Foley Named Corporate Partner of the Year by Wisconsin LGBT Chamber of Commerce
28 April 2015
Foley has been recognized with the Corporate Partner of the Year award by the Wisconsin LGBT Chamber of Commerce. The firm was recognized for its integral role in the formation of the LGBT Bar Association, strong presence on the Wisconsin LGBT Chamber of Commerce’s Leadership Advisory Council and its active LGBT Employee Resource Group to support attorneys and staff.
The Chamber’s annual business awards program recognizes members’ efforts to build a more diverse and inclusive business community in Wisconsin. The awards will be presented at the Chamber’s Business Awards & Expo on May 19, 2015 at the InterContinental Hotel in downtown Milwaukee.
The Chamber’s annual business awards program recognizes members’ efforts to build a more diverse and inclusive business community in Wisconsin. The awards will be presented at the Chamber’s Business Awards & Expo on May 19, 2015 at the InterContinental Hotel in downtown Milwaukee.
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”